2015
DOI: 10.6061/clinics/2015(05)02
|View full text |Cite
|
Sign up to set email alerts
|

Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers

Abstract: OBJECTIVES:The eradication of Helicobacter (H.) pylori allows peptic ulcers in patients infected with the bacteria to be cured. Treatment with the classic triple regimen (proton pump inhibitor, amoxicillin and clarithromycin) has shown decreased efficacy due to increased bacterial resistance to clarithromycin. In our country, the eradication rate by intention to treat with this regimen is 83%. In Brazil, a commercially available regimen for bacterial eradication that uses levofloxacin and amoxicillin with lans… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 28 publications
(29 reference statements)
0
3
0
Order By: Relevance
“…Discrepancies between trial results could be also attributed to ethnic differences, although drug dosage and treatment duration should also be considered. Such impact was suggested by Silva et al who conducted a study on 66 Brazilian patients who had H. pylori infection, did not receive prior treatment, and were treated with levofloxacin triple-based regimen (levofloxacin, amoxicillin, and lansoprazole) showed an eradication rate of 73% (95% CI, 62–84%) compared with 82.7% (95% CI, 79–86%) reported with classic regimen of clarithromycin, amoxicillin, and a PPI [ 17 ]. This finding could be explained by an earlier Brazilian study that found higher rates of resistance by H. pylori to levofloxacin (23%) than to clarithromycin (8%) [ 18 ].…”
Section: Discussionmentioning
confidence: 99%
“…Discrepancies between trial results could be also attributed to ethnic differences, although drug dosage and treatment duration should also be considered. Such impact was suggested by Silva et al who conducted a study on 66 Brazilian patients who had H. pylori infection, did not receive prior treatment, and were treated with levofloxacin triple-based regimen (levofloxacin, amoxicillin, and lansoprazole) showed an eradication rate of 73% (95% CI, 62–84%) compared with 82.7% (95% CI, 79–86%) reported with classic regimen of clarithromycin, amoxicillin, and a PPI [ 17 ]. This finding could be explained by an earlier Brazilian study that found higher rates of resistance by H. pylori to levofloxacin (23%) than to clarithromycin (8%) [ 18 ].…”
Section: Discussionmentioning
confidence: 99%
“…The highest rate in Africa has been reported in Congo Brazzaville [12, 33, 44]; however in the current study, about 59% of patients studied carried known fluoroquinolones resistance mutations. Quinolone resistance to H. pylori has been associated with second line treatment failure [20]; therefore these findings are alarming because a significant proportion of patients on the second line regimen might have treatment failure. This could be explained by the fact that in Tanzania quinolones are commonly used in the treatment of urinary tract infections, typhoid fever, infectious diarrhea, and genital discharge syndrome, hence selecting for H. pylori resistant strains.…”
Section: Discussionmentioning
confidence: 99%
“…Second line regimen includes quinolone based therapy which is alternative after failure of first line regimen. Quinolone resistance to H. pylori has been associated with second line treatment failure in 27% of patients [20]. A mutation in the quinolone-resistance-determining region (QRDR) is responsible for the resistance to quinolones.…”
Section: Introductionmentioning
confidence: 99%